Editor’s note

e-pharmacies cannot be considered a mere extension of the e-commerce boom, simply because the patient cannot tell the difference…

If 2018 was defined by Ayushman Bharat, what will define 2019? As we wind up one year and gear up for the next, I wonder how CEOs…

Merely having an HIV/AIDS Act or NACO’s strategic plan will not help because as NACO’s Director Alok Saxena puts it, human…

Smart companies will focus on discovering avenues which lead to long-term sustainable growth

While the Competition Commission of India (CCI) note appreciates 'legitimate public policy objectives', it tries to determine the…

With saturation in export markets and rising regulatory constraints, will we see a refocus on the domestic market, prodded by…

Framing regulations is one thing, interpreting and implementing them quite another saga, allowing repeat offenders like Biomed to…

The recent faulty hip implant episode proves that our laws have not evolved as fast as medical technology

While there are good intentions, it is the implementation which threatens the viability of  initiatives like the Pharm D course…

Most bigger pharma companies have moved to the next level of exports: the trade of intellectual property, in the form of clinical…

In my Editors Note in last year's Independence Day special issue, I had asked: as we mark our 71st Independence Day this August…

It is ironical that a Chinese movie seems to have done what India's policy makers have been trying to do for many years: get China…

One of the important proposals considered during the 79th Drug Technical Advisory Board (DTAB) meeting held on May 16 was the…

It’s time to count the learnings from Halol, both internally for Sun Pharma as well as for India Pharma Inc

In a speech on May 12, US President Donald Trump put one of his most populist election promises — to make medicines more…